RÉSUMÉ
The article discusses modern approaches to the rational choice of therapy for schizophrenia in accordance with the principles of personalized medicine. Clinical markers for determining the optimal treatment tactics are considered depending on the syndromic features and stereotype of the course of the disease, and the possibility of justified combination therapy with drugs of different pharmacological classes. The specifics of the treatment of schizophrenia in childhood/adolescence and adult are discussed, including the basic principles of choosing drug classes, daily doses and drug therapy tactics.
Sujet(s)
Neuroleptiques , Schizophrénie , Humains , Schizophrénie/traitement médicamenteux , Adulte , Neuroleptiques/usage thérapeutique , Adolescent , Enfant , Facteurs âges , Médecine de précision , Association de médicamentsRÉSUMÉ
This review focuses on late-onset schizophrenia and schizophrenia-like psychosis with very late onset (VLOSLP) with focus on their psychopathologic, neuropsychologic, and neurobiologic aspects. A literature review on late-onset schizophrenia and VLOSLP was conducted based on publications from PubMed, Scopus, and Google Scholar databases up to December 2023. It may be noted that research into schizophrenia has largely focused on early-onset patients, and research into the mental health of older people has focused primarily on dementia and depression, with relatively little information on late-onset schizophrenia and VLOSLP. The nosology of late-onset functional psychoses is still poorly understood. There is currently no consensus on the diagnostic framework for psychosis labeled by the term VLOSLP. These deficiencies need to be addressed in order to understand the background of VLOSLP, the course and prognosis of the illness, and to develop successful management and treatment strategies for these patients, as older adults are more susceptible to the adverse effects of psychotropic medications. Therapy should be holistic, including not only medication but also psychotherapy, and the key role of caregivers of elderly schizophrenia patients should be taken into account. There should be judicious use of pharmacotherapy with an assessment of its risks and benefits.
Sujet(s)
Âge de début , Troubles psychotiques , Schizophrénie , Humains , Schizophrénie/diagnostic , Schizophrénie/traitement médicamenteux , Troubles psychotiques/diagnostic , Troubles psychotiques/étiologie , Sujet âgé , Pronostic , Neuroleptiques/usage thérapeutique , Psychologie des schizophrènesRÉSUMÉ
Olanzapine (OLZ) is an antipsychotic medication used to treat postpartum psychiatric symptoms. It aimed to evaluate the effects of administering OLZ to lactating rats on testicular parameters of adult Wistar rats. Mothers received 2.5, 5 or 10 mg/kg until weaning. Adult male rats showed decrease in body weight, weight of testes, epididymis, prostate, seminal gland and gonadosomatic index when higher doses of OLZ were administered. Testicular volumetric parameters, as well as the length of seminiferous tubules, were also reduced in animals treated with the highest doses of OLZ. The diameter of the seminiferous tubules and the height of the seminiferous epithelium were reduced. There was also a relevant decrease in the population of Sertoli cells and a relevant reduction in the volume of individual Leydig cells. Histopathological analysis of the testes showed lesions compatible with testicular degeneration in rats treated with the highest dose of OLZ. There was a significant reduction in plasma testosterone levels in all treatments. It is noted, therefore, that the adverse impact on the testes of the highest doses of the drug during the neonatal period persisted into adulthood, with the dose of 2.5 mg/kg of OLZ proving to be safer than the others.
Sujet(s)
Neuroleptiques , Benzodiazépines , Lactation , Olanzapine , Rat Wistar , Testicule , Testostérone , Animaux , Mâle , Testicule/effets des médicaments et des substances chimiques , Lactation/effets des médicaments et des substances chimiques , Femelle , Olanzapine/administration et posologie , Neuroleptiques/pharmacologie , Neuroleptiques/administration et posologie , Benzodiazépines/pharmacologie , Benzodiazépines/administration et posologie , Testostérone/sang , Rats , Taille d'organe/effets des médicaments et des substances chimiques , Poids/effets des médicaments et des substances chimiquesRÉSUMÉ
BACKGROUND: Treatment with different antipsychotics can lead to various metabolic side effects in patients with psychosis, impacting long-term prognosis. This study aimed to compare the changes and clinical efficacy of insulin resistance in patients treated with olanzapine and ziprasidone. METHOD: A retrospective analysis was conducted on the clinical data of 80 patients with schizophrenia. The patients were divided into olanzapine treatment group and ziprasidone treatment group. Parameters including body weight, body mass index (BMI), fasting plasma glucose (FPG), fasting plasma insulin (FPI), cholesterol (CHO), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), insulin resistance index, and Positive and Negative Syndrome Scale (PANSS) scores were recorded and compared before and after treatment. RESULTS: BMI, FPG, FPI, homeostatic model assessment of insulin resistance (HOMA-IR), CHO, TG and LDL in both groups were significantly higher than before treatment (p < 0.05). These parameters were significantly higher in the olanzapine group than in the ziprasidone group (p < 0.05). The level of HDL in both groups was significantly decreased after treatment, and the level of HDL in the olanzapine group was significantly lower than that in the ziprasidone group after treatment (p < 0.05). After treatment, the total score and score of PANSS in both groups were significantly lower than before treatment (p < 0.05). After treatment, there was no significant difference in total score and PANSS score between both groups (p > 0.05). The incidence of insulin resistance (IR) was significantly higher in the olanzapine group compared to the ziprasidone group (χ2 = 4.021, p < 0.05). In the IR group, BMI, FPG, FPI, TG, and LDL levels were higher than in the non-IR group (p < 0.05). Multivariate analysis indicated that BMI, FPG, FPI, TG, and LDL were independent risk factors for IR (odd ratio (OR) >1, p < 0.05). CONCLUSIONS: Treatment with olanzapine and ziprasidone improves clinical symptoms in patients with schizophrenia, but increases the risk of insulin resistance. The metabolic side effects of olanzapine are more pronounced.
Sujet(s)
Neuroleptiques , Insulinorésistance , Olanzapine , Schizophrénie , Humains , Neuroleptiques/usage thérapeutique , Neuroleptiques/effets indésirables , Neuroleptiques/administration et posologie , Schizophrénie/traitement médicamenteux , Schizophrénie/sang , Mâle , Femelle , Olanzapine/usage thérapeutique , Olanzapine/effets indésirables , Études rétrospectives , Adulte , Adulte d'âge moyen , Thiazoles/usage thérapeutique , Thiazoles/effets indésirables , Thiazoles/administration et posologie , Pipérazines/usage thérapeutique , Pipérazines/effets indésirables , Pipérazines/administration et posologie , Benzodiazépines/usage thérapeutique , Benzodiazépines/effets indésirablesRÉSUMÉ
BACKGROUND: Readmission, defined as any admission after discharge from the same hospital, has negative implications for health outcomes. This study aims to identify the sociodemographic and clinical factors associated with hospital readmission among psychiatric patients. METHODOLOGY: This case-control study analyzed 202 clinical records of patients admitted to a psychiatric hospital between 2019-2021. The sample was selected using simple random sampling. Qualitative variables were presented using frequencies, percentages, and chi-square tests for association. Quantitative variables were described using central tendency measures and dispersion of data, investigated with the Kolmogorov-Smirnov test, Student's t-test or Wilcoxon test as appropriate. Regression analysis was conducted to determine factors linked to readmission. p < 0.05 was considered. RESULTS: Women accounted for a higher readmission rate (59%). Patients diagnosed with schizophrenia had a higher readmission rate (63%), experienced longer transfer times to the hospital during readmissions, and had shorter hospital stays. Polypharmacy and pharmacological interactions were associated with readmission. Olanzapine treatment was identified as a risk factor for readmission (ExpB = 3.203, 95% CI 1.405-7.306, p = 0.006). CONCLUSIONS: The findings suggest avoiding polypharmacy and medications with high side effect profiles to reduce readmissions. This study offers valuable insights for clinical decision-making from admission to discharge planning, aiming to enhance the quality of care.
Sujet(s)
Troubles mentaux , Sortie du patient , Réadmission du patient , Humains , Réadmission du patient/statistiques et données numériques , Études cas-témoins , Femelle , Mâle , Sortie du patient/statistiques et données numériques , Adulte d'âge moyen , Adulte , Facteurs de risque , Troubles mentaux/thérapie , Troubles mentaux/traitement médicamenteux , Durée du séjour/statistiques et données numériques , Hôpitaux psychiatriques/statistiques et données numériques , Facteurs temps , Schizophrénie/traitement médicamenteux , Schizophrénie/thérapie , Polypharmacie , Olanzapine/usage thérapeutique , Neuroleptiques/usage thérapeutique , Sujet âgéRÉSUMÉ
INTRODUCTION: Cardiovascular morbidity and mortality are high in people with serious mental illness (SMI). This problem is mediated, at least in part, by metabolic side effects of second-generation antipsychotics (SGAs) and by unhealthy lifestyle behaviors. We asked whether oral glucose tolerance testing (oGTT) or hemoglobin A1c (HbA1c) is superior in identifying people with SMI at high cardiometabolic risk and whether this risk is shaped by mood, cognition, or lifestyle habits. METHODS: We evaluated 40 patients with schizophrenia, schizoaffective, or bipolar disorder receiving SGAs by oGTT, HbA1c, comprehensive metabolic and lipid panels, and CRP. Mood was assessed using the Patient Health Questionnaire (PHQ-9), and cognition was assessed using the Saint Louis University Mental Status examination. Diet was assessed using the UK Diabetes and Diet Questionnaire (UKDDQ), and physical activity was assessed using daily step counts. RESULTS: Most patients had prediabetes (preDM) or diabetes mellitus (DM), 72.5% by oGTT, and 52.5% by HbA1c criteria. Pulse rates and insulin resistance indices (Homeostatic Model Assessment of Insulin Resistance, HOMA IR; Matsuda) were significantly different between patients classified as normal or with preDM/DM, using either oGTT or HbA1c criteria. Patients with preDM/DM by HbA1c but not oGTT criteria also had higher waist/hip ratios, triglyceride, and CRP levels (p<0.05). A strong negative correlation was found between average daily step counts and CRP levels (rho = -0.62, p<0.001). Higher UKDDQ scores, or unhealthier diet habits, were associated with higher fasting plasma glucose (rho = 0.28, p = 0.08), triglyceride levels (rho = 0.31, p = 0.05), and insulin resistance (HOMA IR: rho = 0.31, p = 0.06). Higher PHQ-9 scores correlated with lower 2h-oGTT glucose levels (rho = -0.37, p<0.05). CONCLUSIONS: OGTT screening is superior to HbA1c screening in detecting preDM and DM early. Patients identified with preDM/DM by oGTT or HbA1c screening are insulin-resistant and have higher pulse rates. Abdominal obesity, unfavorable lipid profiles, and higher CRP levels were noted in patients screened by HbA1c, but not by oGTT. Low physical activity, low depression scores, and unhealthy diet habits were associated with higher CRP and higher glucose and triglyceride levels, respectively. Future studies should assess the impact of specifically tailored individual lifestyle counseling and medical management interventions in this high-risk population.
Sujet(s)
Affect , Neuroleptiques , Hyperglycémie provoquée , Hémoglobine glyquée , Mode de vie , Humains , Mâle , Femelle , Neuroleptiques/effets indésirables , Neuroleptiques/usage thérapeutique , Adulte d'âge moyen , Hémoglobine glyquée/analyse , Hémoglobine glyquée/métabolisme , Adulte , Affect/effets des médicaments et des substances chimiques , Schizophrénie/traitement médicamenteux , Schizophrénie/sang , Trouble bipolaire/traitement médicamenteux , Trouble bipolaire/complications , Troubles mentaux/traitement médicamenteux , Insulinorésistance , Troubles psychotiques/traitement médicamenteux , Troubles psychotiques/sang , État prédiabétique/sang , Maladies cardiovasculaires/étiologie , Maladies cardiovasculaires/épidémiologie , Diabète/épidémiologieRÉSUMÉ
PURPOSE: This study aims to comprehensively assess the safety of Asenapine by conducting an comprehensive statistical analysis of adverse event reports in the FAERS database, with a particular focus on potential adverse reactions related to its use in the treatment of psychiatric disorders. METHODS: Event reports from the first quarter of 2009 to the third quarter of 2023 were collected and analyzed. Detailed examinations of gender, age, reporter identity, and other aspects were conducted to reveal the fundamental characteristics of Asenapine-related adverse events. Signal mining techniques were employed to systematically evaluate various adverse reactions associated with Asenapine. RESULTS: The study found that adverse event reports involving Asenapine were more common among female patients, with the age group mainly distributed between 18 and 45 years. Physicians were the primary reporters of adverse events, and psychiatric disorders, neurological disorders, and gastrointestinal disorders were the most common areas affected by adverse reactions. In addition to known adverse reactions, potential risks not mentioned in the drug label were identified, such as anosognosia, attentional drift, and psychogenic compensation disorder. CONCLUSION: Asenapine carries the risk of various adverse reactions alongside its therapeutic effects. In clinical practice, physicians should closely monitor the occurrence of neurological disorders, psychiatric disorders, and gastrointestinal system disorders.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments , Neuroleptiques , Bases de données factuelles , Dibenzocycloheptènes , Troubles mentaux , Humains , Femelle , Mâle , Adulte d'âge moyen , Neuroleptiques/effets indésirables , Troubles mentaux/traitement médicamenteux , Troubles mentaux/induit chimiquement , Adulte , Adolescent , Jeune adulte , Maladies du système nerveux/induit chimiquement , Sujet âgé , Composés hétérocycliques avec 4 noyaux ou plus/effets indésirablesRÉSUMÉ
OBJECTIVES: Negative symptoms in schizophrenia are associated with significant illness burden. We sought to investigate clinical outcomes for patients with schizophrenia who present with predominant negative symptoms (PNS) vs without PNS. DESIGN: Retrospective analysis of electronic health record (EHR) data. SETTING: 25 US providers of mental healthcare. PARTICIPANTS: 4444 adults with schizophrenia receiving care between 1999 and 2020. EXPOSURE: PNS defined as ≥3 negative symptoms and ≤3 positive symptoms recorded in EHR data at the time of the first recorded schizophrenia diagnosis (index date). Symptom data were ascertained using natural language processing applied to semistructured free text records documenting the mental state examination. A matched sample (1:1) of patients without PNS was used to compare outcomes. Follow-up data were obtained up to 12 months following the index date. PRIMARY OUTCOME MEASURE: Mean number of psychiatric hospital admissions. SECONDARY OUTCOME MEASURES: Mean number of outpatient visits, estimated treatment costs, Clinical Global Impression - Severity score and antipsychotic treatments (12 months before and after index date). RESULTS: 360 (8%) patients had PNS and 4084 (92%) did not have PNS. Patients with PNS were younger (36.4 vs 39.7 years, p<0.001) with a greater prevalence of psychiatric comorbidities (schizoaffective disorders: 25.0 vs 18.4%, p=0.003; major depressive disorder: 17.8 vs 9.8%, p<0.001). During follow-up, patients with PNS had fewer days with an antipsychotic prescription (mean=111.8 vs 140.9 days, p<0.001). Compared with matched patients without PNS, patients with PNS were more likely to have a psychiatric inpatient hospitalisation (76.1% vs 59.7%, p<0.001) and had greater estimated inpatient costs ($16 893 vs $13 732, p=0.04). CONCLUSIONS: Patients with PNS were younger and presented with greater illness severity and more psychiatric comorbidities compared with patients without PNS. Our findings highlight an unmet need for novel therapeutic approaches to address negative symptoms to improve clinical outcomes.
Sujet(s)
Neuroleptiques , Dossiers médicaux électroniques , Schizophrénie , Humains , Schizophrénie/thérapie , Schizophrénie/économie , Femelle , Mâle , Adulte , Études rétrospectives , Adulte d'âge moyen , Neuroleptiques/usage thérapeutique , Neuroleptiques/économie , Acceptation des soins par les patients/statistiques et données numériques , États-Unis/épidémiologie , Hospitalisation/économie , Hospitalisation/statistiques et données numériques , Coûts des soins de santé/statistiques et données numériquesRÉSUMÉ
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or conditions. These discussions have given rise to rounds reports that will prove useful for clinicians practicing at the interface of medicine and psychiatry.Prim Care Companion CNS Disord 2024;26(4):23f03702. Author affiliations are listed at the end of this article.
Sujet(s)
Neuroleptiques , Clozapine , Humains , Clozapine/effets indésirables , Clozapine/usage thérapeutique , Neuroleptiques/usage thérapeutique , Neuroleptiques/effets indésirables , Schizophrénie/traitement médicamenteuxRÉSUMÉ
Cariprazine represents a new generation of antipsychotic medication, characterized by its heightened affinity for the D3 receptor. It has recently obtained approval as an adjunctive treatment option for patients diagnosed with major depressive disorder. In this study, a novel approach utilizing fluorescence spectroscopy was developed to analyze cariprazine. The methodology involves the transformation of cariprazine into a fluorescent compound by means of chemical derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl). Following excitation at 470 nm, the fluorescent derivative displayed peak fluorescence emission at 550 nm. The factors influencing the derivatization process were optimized. Upon reaching the optimal reaction conditions, a linear correlation (r2 = 0.9995) was observed between the fluorescence intensity and concentrations of cariprazine ranging from 20 to 400 ng/ml. Detection and quantitation limits were determined to be 5.85 and 17.74 ng/ml, respectively. The approach was accurate and precise, with percent recovery values ranging from 98.14% to 99.91% and relative standard deviations of less than 2%. Application of the method to the analysis of cariprazine in bulk and commercial capsules forms yielded accurate results. Moreover, adherence to environmentally friendly analytical practices was evident through alignment with the principles of green analysis, as demonstrated by the analytical eco-scale, AGREE, and GAPI greenness assessment tools.
Sujet(s)
Pipérazines , Spectrométrie de fluorescence , Pipérazines/composition chimique , Pipérazines/analyse , Technologie de la chimie verte , Neuroleptiques/composition chimique , Structure moléculaire , Limite de détectionRÉSUMÉ
PURPOSE: This study aimed to create and validate robust machine-learning-based prediction models for antipsychotic drug (risperidone) continuation in children and teenagers suffering from mania over one year and to discover potential variables for clinical treatment. METHOD: The study population was collected from the national claims database in China. A total of 4,532 patients aged 4-18 who began risperidone therapy for mania between September 2013 and October 2019 were identified. The data were randomly divided into two datasets: training (80%) and testing (20%). Five regularly used machine learning methods were employed, in addition to the SuperLearner (SL) algorithm, to develop prediction models for the continuation of atypical antipsychotic therapy. The area under the receiver operating characteristic curve (AUC) with a 95% confidence interval (CI) was utilized. RESULTS: In terms of discrimination and robustness in predicting risperidone treatment continuation, the generalized linear model (GLM) performed the best (AUC: 0.823, 95% CI: 0.792-0.854, intercept near 0, slope close to 1.0). The SL model (AUC: 0.823, 95% CI: 0.791-0.853, intercept near 0, slope close to 1.0) also exhibited significant performance. Furthermore, the present findings emphasize the significance of several unique clinical and socioeconomic variables, such as the frequency of emergency room visits for nonmental health disorders. CONCLUSIONS: The GLM and SL models provided accurate predictions regarding risperidone treatment continuation in children and adolescents with episodes of mania and hypomania. Consequently, applying prediction models in atypical antipsychotic medicine may aid in evidence-based decision-making.
Sujet(s)
Neuroleptiques , Apprentissage machine , Manie , Rispéridone , Humains , Adolescent , Neuroleptiques/usage thérapeutique , Femelle , Rispéridone/usage thérapeutique , Mâle , Enfant , Manie/traitement médicamenteux , Enfant d'âge préscolaire , Chine , Trouble bipolaire/traitement médicamenteux , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Severe psychomotor agitation and aggression often require immediate pharmacological intervention, but clear evidence-based recommendations for choosing among the multiple options are lacking. To address this gap, we plan a systematic review and individual-participant-data network meta-analysis to investigate their comparative effectiveness in real-world emergency settings with increased precision. METHODS: We will include randomized controlled trials investigating intramuscular or intravenous pharmacological interventions, as monotherapy or in combination, in adults with severe psychomotor agitation irrespective of the underlying diagnosis and requiring rapid tranquilization in general or psychiatric emergency settings. We will exclude studies before 2002, those focusing on specific reasons for agitation and placebo-controlled trials to avoid concerns related to the transitivity assumption and potential selection biases. We will search for eligible studies in BIOSIS, CENTRAL, CINAHL Plus, Embase, LILACS, MEDLINE via Ovid, PubMed, ProQuest, PsycINFO, ClinicalTrials.gov, and WHO-ICTRP. Individual-participant data will be requested from the study authors and harmonized into a uniform format, and aggregated data will also be extracted from the studies. At least two independent reviewers will conduct the study selection, data extraction, risk-of-bias assessment using RoB 2, and applicability evaluation using the RITES tool. The primary outcome will be the number of patients achieving adequate sedation within 30 min after treatment, with secondary outcomes including the need for additional interventions and adverse events, using odds ratios as the effect size. If enough individual-participant data will be collected, we will synthesize them in a network meta-regression model within a Bayesian framework, incorporating study- and participant-level characteristics to explore potential sources of heterogeneity. In cases where individual-participant data are unavailable, potential data availability bias will be explored, and models allowing for the inclusion of studies reporting only aggregated data will be considered. We will assess the confidence in the evidence using the Confidence in Network Meta-Analysis (CINeMA) approach. DISCUSSION: This individual-participant-data network meta-analysis aims to provide a fine-tuned synthesis of the evidence on the comparative effectiveness of pharmacological interventions for severe psychomotor agitation in real-world emergency settings. The findings from this study can greatly be provided clearer evidence-based guidance on the most effective treatments. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023402365.
Sujet(s)
Méta-analyse en réseau , Agitation psychomotrice , Revues systématiques comme sujet , Humains , Agitation psychomotrice/traitement médicamenteux , Essais contrôlés randomisés comme sujet , Plan de recherche , Neuroleptiques/usage thérapeutiqueRÉSUMÉ
Clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. We present a patient with a diagnosis of schizoaffective disorder who was stable on clozapine for a decade until discontinuation due to thrombocytopenia. She experienced a relapse of her illness, presenting with psychotic and catatonic features with poor oral intake and physical health complications requiring a lengthy admission to the hospital. There was a poor response to alternative antipsychotics and a full course of electroconvulsive therapy. Intramuscular (IM) clozapine was initiated due to catatonia and refusal to accept oral medications. After receiving 10 doses of IM clozapine, she started accepting oral clozapine and made a full recovery within a few weeks. The low platelet count was persistent, and a bone marrow biopsy showed results consistent with immune thrombocytopenia being the cause of that low platelet count.
Sujet(s)
Neuroleptiques , Catatonie , Clozapine , Thrombopénie , Humains , Clozapine/effets indésirables , Clozapine/administration et posologie , Clozapine/usage thérapeutique , Thrombopénie/induit chimiquement , Thrombopénie/traitement médicamenteux , Femelle , Catatonie/traitement médicamenteux , Injections musculaires , Neuroleptiques/administration et posologie , Neuroleptiques/effets indésirables , Neuroleptiques/usage thérapeutique , Troubles psychotiques/traitement médicamenteux , Résultat thérapeutique , Adulte d'âge moyenRÉSUMÉ
Ayahuasca is a plant-based psychoactive decoction, traditionally used by indigenous Amazonian peoples, which commonly contains the hallucinogen N,N-dimethyltryptamine (DMT). There is now growing interest across the Western world in psychedelics including Ayahuasca.This case describes a previously well male with no risk factors for adverse psychiatric outcomes or forensic history. Following controlled Ayahuasca use, he developed an enduring psychotic episode, during which he significantly assaulted a relative and was admitted to a forensic psychiatric unit. He was treated with the antipsychotic aripiprazole, and his psychotic symptoms abated. 18 months following his admission, recovery has been sustained.Previous case reports have described psychosis following Ayahuasca ingestion, but typically of short duration in patients with a personal or family history of psychiatric illness, or in those taking other substances. With the growing use of Ayahuasca, it is important to highlight that adverse effects may include more prolonged psychotic symptoms and the risk of psychotically mediated violence.
Sujet(s)
Banisteriopsis , Hallucinogènes , Psychoses toxiques , Humains , Mâle , Banisteriopsis/effets indésirables , Psychoses toxiques/étiologie , Psychoses toxiques/diagnostic , Hallucinogènes/effets indésirables , Adulte , Neuroleptiques/effets indésirables , Psychiatrie légaleRÉSUMÉ
Objective: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic, has 2 initiation options: 1-day (AL NanoCrystal Dispersion [ALNCD] injection plus 30 mg oral aripiprazole on day 1 only) and 21-day (15 mg oral aripiprazole for 21 days). This post hoc analysis assessed the safety and tolerability of both initiation approaches.Methods: We analyzed data from the first 4 weeks of 2 AL studies, one using the 1-day initiation regimen (conducted between November 2017 and March 2019) and the other using the 21-day initiation regimen (conducted between December 2011 and March 2014). Outcomes of interest during the matched 4-week period included the likelihood of adverse events (AEs), including those associated with discontinuation, rated as serious, or of special interest (injection site reactions [ISRs] and akathisia).Results: The 1-day (n = 99) and 21-day (n = 415) initiation regimens had comparable rates of AEs (57.6% and 52.0%, respectively; most were mild), serious AEs (2.0% and 1.4%), and AEs leading to discontinuation (4.0% and 3.1%). The incidence of ISRs was 11.1% after the ALNCD injection (day 1) in the 1-day initiation regimen. ISR rates for the AL starting doses were 9.2% for the 1-day regimen (AL 1064 mg on day 8) and 3.9% for the 21-day regimen (AL 441 mg/882 mg on day 1). Rates of akathisia were 9.1% and 11.1% for the 1-day and 21-day regimens, respectively. One patient discontinued because of an ISR in the 21-day study, and 2 patients in the 21-day study discontinued because of akathisia. Mean changes from baseline in week 4 Positive and Negative Syndrome Scale total scores were -17.4 (1-day) and -19.5 (21-day).Conclusions: Four-week safety and tolerability were similar following the initiation of AL with either the 1-day or 21-day regimen, supporting the utility of both initiation regimens. Engaging patients in discussions regarding options for initiating AL may help facilitate shared decision-making and personalization of treatment for patients with schizophrenia.Trial Registration: ClinicalTrials.gov identifiers: NCT03345979 and NCT01469039.
Sujet(s)
Neuroleptiques , Aripiprazole , Calendrier d'administration des médicaments , Humains , Aripiprazole/administration et posologie , Aripiprazole/effets indésirables , Neuroleptiques/administration et posologie , Neuroleptiques/effets indésirables , Femelle , Mâle , Adulte , Adulte d'âge moyen , Administration par voie orale , Préparations à action retardée , Schizophrénie/traitement médicamenteux , Jeune adulte , Troubles psychotiques/traitement médicamenteuxRÉSUMÉ
According to this study: Use of antipsychotics in patients with dementia is associated with an increased risk of a wide range of serious adverse outcomes, particularly soon after the initiation of treatment.Antipsychotics are associated with a wider range of risks than previously known, and any potential benefits must be weighed against the risk of serious harm.
Sujet(s)
Neuroleptiques , Démence , Humains , Neuroleptiques/effets indésirables , Neuroleptiques/usage thérapeutique , Démence/traitement médicamenteux , Sujet âgé , Femelle , Mâle , Facteurs de risque , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: Clozapine is known to cause agranulocytosis. Mandatory monitoring schemes are aimed at reducing the risk of agranulocytosis and of the consequences of agranulocytosis. All cases of agranulocytosis occurring in people prescribed clozapine are assumed to be caused by clozapine. METHODS: In a previous study, we examined a cohort of patients listed on our hospital database as having had clozapine-induced agranulocytosis and applied specific criteria to identify those with confirmed clozapine-related, life-threatening agranulocytosis. In this study, we examine the cases not meeting these specific criteria. RESULTS: In the original study, 9 of 23 cases met the criteria for clozapine-induced, life-threatening agranulocytosis. Of the 13 remaining cases for whom data were available, 5 were probably caused by clozapine but were not life-threatening. Three cases were the result of concomitant cancer chemotherapy. Three were anomalous results probably related to measurement error. For the remaining two cases, the cause was not identified. CONCLUSION: Not all cases of agranulocytosis occurring in people taking clozapine are caused by clozapine. The widely used threshold criterion-based diagnosis overestimates the risk of agranulocytosis. True clozapine-related agranulocytosis is best identified by pattern-based criteria: rapid fall in neutrophil counts over around 2 weeks to below 0.5 × 109/L for two consecutive days (unless clozapine is stopped very early or granulocyte colony stimulating factor is given) where other possible causes (benign ethnic neutropenia, cancer chemotherapy) can be ruled out.
Sujet(s)
Agranulocytose , Neuroleptiques , Clozapine , Neutropénie , Clozapine/effets indésirables , Humains , Neutropénie/induit chimiquement , Neuroleptiques/effets indésirables , Agranulocytose/induit chimiquement , Mâle , Femelle , Adulte , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TNE) overlap is a rare skin disorder characterized by erythema, blisters, extensive exfoliation, epidermal detachment, the involvement of multiple mucosae, and positive Nikolsky's sign. SJS-TEN has a high mortality rate. Our case involves a rare occurrence of drug-induced Stevens-Johnson syndrome-toxic epidermal necrolysis overlap with a delayed onset in the setting of quetiapine and famotidine therapy. CASE PRESENTATION: An 82-year-old Taiwanese female was admitted to our hospital for decreased urine output, generalized edema, and multiple skin blisters and bedsores. With further spread of the lesions, multiple ruptured bullae with shallow erosions on the face, trunk, and limbs and mucosal involvement affected 20% of the total body surface area. Nikolsky's sign was positive. A diagnosis of Steven-Johnson syndrome was highly suspected. One month prior, she had started famotidine and quetiapine. Intravenous methylprednisolone treatment was initiated, which ameliorated the skin lesions after 3 days. However, new lesions developed after only 1 day of methylprednisolone tapering. The patient died 12 days after admission. CONCLUSION: Stevens-Johnson syndrome-toxic epidermal necrolysis is a rare skin disorder. Although it is mainly acute and has a high mortality rate, delayed onset can still occur. Quetiapine and famotidine are generally safe and effective for treating geriatric and gastrointestinal problems, but rare drug hypersensitivity reactions can lead to debilitating consequences. Therefore, increased clinical awareness and the initiation of supportive care are imperative. Optimal management guidelines are still lacking, and confirmation of developed guidelines through randomized controlled trials is needed. Collaboration for better management strategies is warranted.
Sujet(s)
Neuroleptiques , Famotidine , Fumarate de quétiapine , Syndrome de Stevens-Johnson , Humains , Syndrome de Stevens-Johnson/étiologie , Syndrome de Stevens-Johnson/traitement médicamenteux , Femelle , Famotidine/usage thérapeutique , Fumarate de quétiapine/effets indésirables , Fumarate de quétiapine/usage thérapeutique , Sujet âgé de 80 ans ou plus , Neuroleptiques/effets indésirables , Issue fataleRÉSUMÉ
Schizophrenia is a disease with a complex etiology that significantly impairs the functioning of patients. In recent years, there has been increasing focus on the importance of the gut microbiota in the context of the gut-brain axis. In our study, we analyzed data on the gut-brain axis in relation to schizophrenia, as well as the impacts of eating habits, the use of various supplements, and diets on schizophrenia. Additionally, the study investigated the impact of antipsychotics on the development of metabolic disorders, such as diabetes, dyslipidemia, and obesity. There may be significant clinical benefits to be gained from therapies supported by supplements such as omega-3 fatty acids, B vitamins, and probiotics. The results suggest the need for a holistic approach to the treatment of schizophrenia, incorporating both drug therapy and dietary interventions.
Sujet(s)
Axe cerveau-intestin , Régime alimentaire , Compléments alimentaires , Microbiome gastro-intestinal , Probiotiques , Schizophrénie , Humains , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Probiotiques/administration et posologie , Neuroleptiques/administration et posologie , Acides gras omega-3/administration et posologie , Comportement alimentaireRÉSUMÉ
Pharmacogenetic markers are current targets for the personalized treatment of psychosis. Limited data exist on COMT and NRG1 polymorphisms in relation to risperidone treatment. This study focuses on the impact of COMT rs4680 and NRG1 (rs35753505, rs3924999) polymorphisms on risperidone treatment in schizophrenia spectrum disorders (SSDs). This study included 103 subjects with SSD treated with risperidone monotherapy. COMT rs4680, NRG1 rs35753505, and rs3924999 were analyzed by RT-PCR. Participants were evaluated via the Positive and Negative Syndrome Scale (PANSS) after six weeks. Socio-demographic and clinical characteristics were collected. COMT rs4680 genotypes significantly differed in PANSS N scores at admission: AG>AA genotypes (p = 0.03). After six weeks of risperidone, PANSS G improvement was AA>GG (p = 0.05). The PANSS total score was as follows: AA>AG (p = 0.04), AA>GG (p = 0.02). NRG1 rs35753504 genotypes significantly differed across educational levels, with CC>CT (p = 0.02), and regarding the number of episodes, TT>CC, CT>CC (p = 0.01). The PANSS total score after six weeks of treatment showed a better improvement for TTSujet(s)
Neuroleptiques
, Catechol O-methyltransferase
, Neuréguline-1
, Polymorphisme de nucléotide simple
, Rispéridone
, Schizophrénie
, Humains
, Neuréguline-1/génétique
, Catechol O-methyltransferase/génétique
, Rispéridone/usage thérapeutique
, Schizophrénie/traitement médicamenteux
, Schizophrénie/génétique
, Mâle
, Femelle
, Adulte
, Neuroleptiques/usage thérapeutique
, Adulte d'âge moyen
, Médecine de précision/méthodes
, Génotype